CN103342789B - 用于向细胞内递送的二嵌段共聚物和其多核苷酸复合物 - Google Patents

用于向细胞内递送的二嵌段共聚物和其多核苷酸复合物 Download PDF

Info

Publication number
CN103342789B
CN103342789B CN201310232498.XA CN201310232498A CN103342789B CN 103342789 B CN103342789 B CN 103342789B CN 201310232498 A CN201310232498 A CN 201310232498A CN 103342789 B CN103342789 B CN 103342789B
Authority
CN
China
Prior art keywords
alkyl
residues
residue
copolymer
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201310232498.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN103342789A (zh
Inventor
P·S·斯泰顿
A·S·霍夫曼
A·J·康弗汀
D·贝诺伊特
C·L·杜瓦尔
P·约翰逊
A·加尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
PhaseRx Inc
Original Assignee
University of Washington
PhaseRx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, PhaseRx Inc filed Critical University of Washington
Publication of CN103342789A publication Critical patent/CN103342789A/zh
Application granted granted Critical
Publication of CN103342789B publication Critical patent/CN103342789B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F299/00—Macromolecular compounds obtained by interreacting polymers involving only carbon-to-carbon unsaturated bond reactions, in the absence of non-macromolecular monomers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
    • C08F293/005—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule using free radical "living" or "controlled" polymerisation, e.g. using a complexing agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/10—Esters
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
CN201310232498.XA 2008-05-13 2009-05-13 用于向细胞内递送的二嵌段共聚物和其多核苷酸复合物 Expired - Fee Related CN103342789B (zh)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US5290808P 2008-05-13 2008-05-13
US5291408P 2008-05-13 2008-05-13
US61/052,914 2008-05-13
US61/052,908 2008-05-13
US9129408P 2008-08-22 2008-08-22
US61/091,294 2008-08-22
US11205408P 2008-11-06 2008-11-06
US11204808P 2008-11-06 2008-11-06
US61/112,048 2008-11-06
US61/112,054 2008-11-06
US12076908P 2008-12-08 2008-12-08
US61/120,769 2008-12-08
US14077408P 2008-12-24 2008-12-24
US14077908P 2008-12-24 2008-12-24
US61/140,774 2008-12-24
US61/140,779 2008-12-24
US17137709P 2009-04-21 2009-04-21
US61/171,377 2009-04-21
CN2009801228883A CN102083878B (zh) 2008-05-13 2009-05-13 用于向细胞内递送的二嵌段共聚物和其多核苷酸复合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2009801228883A Division CN102083878B (zh) 2008-05-13 2009-05-13 用于向细胞内递送的二嵌段共聚物和其多核苷酸复合物

Publications (2)

Publication Number Publication Date
CN103342789A CN103342789A (zh) 2013-10-09
CN103342789B true CN103342789B (zh) 2016-11-23

Family

ID=41319323

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201310232498.XA Expired - Fee Related CN103342789B (zh) 2008-05-13 2009-05-13 用于向细胞内递送的二嵌段共聚物和其多核苷酸复合物
CN2009801228883A Expired - Fee Related CN102083878B (zh) 2008-05-13 2009-05-13 用于向细胞内递送的二嵌段共聚物和其多核苷酸复合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2009801228883A Expired - Fee Related CN102083878B (zh) 2008-05-13 2009-05-13 用于向细胞内递送的二嵌段共聚物和其多核苷酸复合物

Country Status (13)

Country Link
US (3) US9476063B2 (enExample)
EP (2) EP2620161A1 (enExample)
JP (2) JP5911723B2 (enExample)
KR (1) KR101661636B1 (enExample)
CN (2) CN103342789B (enExample)
AU (1) AU2009246327B8 (enExample)
BR (1) BRPI0912159B8 (enExample)
CA (3) CA2724105C (enExample)
ES (1) ES2404131T3 (enExample)
IL (1) IL209238A (enExample)
MX (1) MX2010012238A (enExample)
WO (1) WO2009140427A2 (enExample)
ZA (1) ZA201008729B (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2296708A4 (en) 2008-05-13 2011-10-26 Univ Washington POLYMER CARRIER
JP5755563B2 (ja) 2008-05-13 2015-07-29 ユニヴァーシティ オブ ワシントン ミセル集合体
AU2009246327B8 (en) 2008-05-13 2013-10-03 Phaserx, Inc. Diblock copolymers and polynucleotide complexes thereof for delivery into cells
US9211250B2 (en) 2008-08-22 2015-12-15 University Of Washington Heterogeneous polymeric micelles for intracellular delivery
CA2742955A1 (en) 2008-11-06 2010-05-14 University Of Washington Bispecific intracellular delivery vehicles
AU2009313358B2 (en) 2008-11-06 2013-06-06 Phaserx, Inc. Multiblock copolymers
EP2373715A4 (en) 2008-12-08 2014-12-03 Univ Washington OMEGA FUNCTIONALIZED POLYMERS, TRANSITIONALIZED BLOCK COPOLYMERS, POLYMER BIOKON JUGATES, AND RADICAL CHAIN EXTENSION POLICY RESPONSE
WO2011060281A1 (en) * 2009-11-13 2011-05-19 University Of Washington Through Its Center For Commercialization Hydrophobic block conjugated therapeutic agents
US9415113B2 (en) 2009-11-18 2016-08-16 University Of Washington Targeting monomers and polymers having targeting blocks
CA2794307A1 (en) 2010-03-26 2011-09-29 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2821992A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
CN104024328A (zh) 2011-08-26 2014-09-03 箭头研究公司 用于体内核酸递送的聚(乙烯基酯)聚合物
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
AU2012308686B2 (en) * 2011-09-13 2018-05-10 Monsanto Technology Llc Methods and compositions for weed control
HRP20220250T1 (hr) 2011-10-03 2022-04-29 Modernatx, Inc. Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe
SI2791160T1 (sl) 2011-12-16 2022-07-29 Modernatx, Inc. Sestave modificirane MRNA
AU2013243952A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
BR112014004528A2 (pt) 2012-04-18 2019-09-24 Arrowhead Res Corp polímeros de poli(acrilato) para entrega de ácido nucleico in vivo
JP6195171B2 (ja) 2012-04-27 2017-09-13 国立大学法人 東京大学 核酸デリバリー用ユニット構造型医薬組成物
US10240161B2 (en) 2012-05-24 2019-03-26 A.B. Seeds Ltd. Compositions and methods for silencing gene expression
US10046086B2 (en) 2012-09-21 2018-08-14 Vanderbilt University Poly(thioketal-urethane) scaffolds and methods of use
WO2014047524A1 (en) 2012-09-21 2014-03-27 Vanderbilt University Poly(thioketal-urethane) scaffolds and methods of use
SMT202200337T1 (it) 2012-11-26 2022-09-14 Modernatx Inc Rna modificato al livello del terminale
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CA2919828C (en) * 2013-07-30 2022-07-19 Phaserx, Inc. Block copolymers and their conjugates or complexes with oligonucleotides
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
CA2931547A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
SI3116900T1 (sl) 2014-03-09 2021-02-26 The Trustees Of The University Of Pennsylvania Sestavki uporabni pri zdravljenju pomanjkanja ornitin transkarbamilaze(OTC)
US11318206B2 (en) 2014-03-28 2022-05-03 Aposense Ltd Compounds and methods for trans-membrane delivery of molecules
MX2016012716A (es) * 2014-03-28 2017-08-16 Aposense Ltd Compuestos y metodos para suministro trans-membrana de moleculas.
US9993563B2 (en) * 2014-03-28 2018-06-12 Aposense Ltd. Compounds and methods for trans-membrane delivery of molecules
US10695288B2 (en) 2014-11-19 2020-06-30 Vanderbilt University Reactive oxygen species (ROS)-responsive compositions and methods thereof
WO2016118697A1 (en) * 2015-01-21 2016-07-28 Phaserx, Inc. Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
WO2016130600A2 (en) 2015-02-09 2016-08-18 Duke University Compositions and methods for epigenome editing
US20180110877A1 (en) 2015-04-27 2018-04-26 The Trustees Of The University Of Pennsylvania DUAL AAV VECTOR SYSTEM FOR CRISPR/Cas9 MEDIATED CORRECTION OF HUMAN DISEASE
WO2017015637A1 (en) 2015-07-22 2017-01-26 Duke University High-throughput screening of regulatory element function with epigenome editing technologies
KR102699944B1 (ko) 2015-08-25 2024-09-13 듀크 유니버시티 Rna-가이드된 엔도뉴클레아제를 이용하는 게놈 조작에서 특이성을 개선하는 조성물 및 방법
WO2017066497A2 (en) 2015-10-13 2017-04-20 Duke University Genome engineering with type i crispr systems in eukaryotic cells
US10947338B2 (en) * 2016-03-29 2021-03-16 Lg Chem, Ltd. Block polymer and polymer electrolyte membrane comprising same
US20190127713A1 (en) 2016-04-13 2019-05-02 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
EP4275747A3 (en) 2016-07-19 2024-01-24 Duke University Therapeutic applications of cpf1-based genome editing
MX2019002339A (es) 2016-09-02 2019-05-16 Dicerna Pharmaceuticals Inc Analogos de 4'-fosfato y oligonucleotidos que los comprenden.
WO2018126084A1 (en) 2016-12-30 2018-07-05 Phaserx, Inc. Branched peg molecules and related compositions and methods
KR20190104392A (ko) 2017-01-09 2019-09-09 아포센스 엘티디. 분자의 막투과 전달을 위한 화합물 및 방법
WO2018232357A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna formulations
US11744801B2 (en) 2017-08-31 2023-09-05 Modernatx, Inc. Methods of making lipid nanoparticles
CN111050752B (zh) 2017-08-31 2022-08-16 国立大学法人东京大学 搭载核酸的单元型聚离子复合物
WO2019130319A1 (en) 2018-01-01 2019-07-04 Aposense Ltd. Compounds and methods for trans-membrane delivery of molecules
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
WO2020092633A1 (en) * 2018-10-30 2020-05-07 Vanderbilt University Graft copolymers, methods of forming graft copolymers, and methods of use thereof
JP7389055B2 (ja) * 2019-01-09 2023-11-29 デンカ株式会社 トリブロック共重合体及びトリブロック共重合体の製造方法
WO2020205473A1 (en) 2019-03-29 2020-10-08 Decerna Pharmaceuticals, Inc. Compositions and methods for the treatment of kras associated diseases or disorders
BR112021021686A2 (pt) 2019-05-03 2022-03-22 Dicerna Pharmaceuticals Inc Moléculas inibidoras de ácido nucleico de fita dupla com fitas senso curtas
CA3163857A1 (en) 2020-01-15 2021-07-22 Weimin Wang 4'-o-methylene phosphonate nucleic acids and analogues thereof
KR20230004841A (ko) * 2020-04-30 2023-01-06 다우 글로벌 테크놀로지스 엘엘씨 Raft 중합에 의해 올레핀-아크릴레이트 블록 공중합체를 제조하는 방법
AU2021321289A1 (en) 2020-08-04 2023-03-02 Dicerna Pharmaceuticals, Inc. Systemic delivery of oligonucleotides
CN113087017A (zh) * 2021-04-06 2021-07-09 中国科学院理化技术研究所 一种偏钒酸钠纳米球及其制备方法和应用
CN119731321A (zh) 2022-06-24 2025-03-28 图恩疗法股份有限公司 通过靶向基因阻遏减少低密度脂蛋白的组合物、系统和方法
WO2025072893A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for non-viral gene delivery
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025250979A1 (en) 2024-05-31 2025-12-04 Battelle Memorial Institute Polymer nanoparticle compositions for non-viral gene delivery

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006016166A1 (en) * 2004-08-13 2006-02-16 Asahi Kasei Kabushiki Kaisha Polymers useful as medical materials
US20070224241A1 (en) * 2006-03-16 2007-09-27 Washington, University Of TEMPERATURE- AND pH-RESPONSIVE POLYMER COMPOSITIONS

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4877603A (en) 1987-12-18 1989-10-31 The Procter & Gamble Company Oral compositions
US6359054B1 (en) 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
FR2767829B1 (fr) 1997-09-01 1999-12-03 Georges Sturtz Composes phosphonates ou gem-bisphosphonates acryliques ou methacryliques
US6410057B1 (en) 1997-12-12 2002-06-25 Samyang Corporation Biodegradable mixed polymeric micelles for drug delivery
AR018528A1 (es) 1997-12-12 2001-11-28 Expression Genetics Inc Mezcla polimerica biodegradable de micelas para transferencia genetica
US6383811B2 (en) 1997-12-30 2002-05-07 Mirus Corporation Polyampholytes for delivering polyions to a cell
EP1044021B1 (en) 1998-01-05 2009-09-23 The University of Washington Enhanced transport using membrane disruptive agents
US6306994B1 (en) * 1999-05-14 2001-10-23 E. I. Du Pont De Nemours And Company Inks with enhanced substrate binding characteristics
US7098032B2 (en) 2001-01-02 2006-08-29 Mirus Bio Corporation Compositions and methods for drug delivery using pH sensitive molecules
US7033607B2 (en) 1999-12-31 2006-04-25 Mirus Bio Corporation pH-titratable polyampholytes for delivering polyions to a cell
WO2001051092A2 (en) 2000-01-07 2001-07-19 University Of Washington Enhanced transport of agents using membrane disruptive agents
US20030134420A1 (en) 2000-02-18 2003-07-17 Lollo Charles Peter Methods and compositions for gene delivery
AU2001276627A1 (en) 2000-05-17 2001-11-26 Labopharm Inc. Drug containing polymeric micelles
ATE365753T1 (de) 2000-10-06 2007-07-15 Biocompatibles Uk Ltd Zwitterionische polymere
SE517421C2 (sv) 2000-10-06 2002-06-04 Bioglan Ab Mikropartiklar, lämpade för parenteral administration, väsentligen bestående av stärkelse med minst 85 % amylopektin och med reducerad molekylvikt, samt framställning därav
WO2003087188A1 (en) 2001-04-26 2003-10-23 Nanosphere, Inc. Oligonucleotide-modified romp polymers and co-polymers
US6939564B2 (en) 2001-06-08 2005-09-06 Labopharm, Inc. Water-soluble stabilized self-assembled polyelectrolytes
US6780428B2 (en) 2001-06-08 2004-08-24 Labopharm, Inc. Unimolecular polymeric micelles with an ionizable inner core
US7094810B2 (en) 2001-06-08 2006-08-22 Labopharm, Inc. pH-sensitive block copolymers for pharmaceutical compositions
WO2003059382A2 (en) 2001-12-28 2003-07-24 Supratek Pharma Inc. Pharmaceutical compositions comprising polyanionic polymers and amphiphilic block copolymers and methods of use thereof to improve gene expression
EP1480619B1 (en) 2002-03-07 2013-08-07 Biocompatibles UK Limited Drug carriers comprising amphiphilic block copolymers
US7229973B2 (en) 2002-05-19 2007-06-12 You Han Bae pH-sensitive polymeric micelles for drug delivery
EP1400555A1 (en) 2002-09-17 2004-03-24 Kawamura Institute Of Chemical Research Water-soluble block copolymer and production method therefor
JP2006505686A (ja) * 2002-11-07 2006-02-16 ロディア・シミ 両性又は双極性イオン性部分を含む制御された構造のコポリマー
WO2004050795A2 (en) 2002-11-27 2004-06-17 Tufts University Antioxidant-functionalized polymers
AU2003300380B2 (en) 2002-12-30 2008-11-06 Nektar Therapeutics Multi-arm polypeptide-poly(ethylene glycol) block copolymers as drug delivery vehicles
US7871818B2 (en) 2003-01-31 2011-01-18 Roche Madison Inc. Membrane active polymers
US7217776B1 (en) 2003-02-14 2007-05-15 Iowa State University Research Foundation pH-sensitive methacrylic copolymer gels and the production thereof
US20040162235A1 (en) 2003-02-18 2004-08-19 Trubetskoy Vladimir S. Delivery of siRNA to cells using polyampholytes
JP4535229B2 (ja) 2003-05-08 2010-09-01 国立大学法人 東京大学 ポリエチレングリコール−ポリカチオンブロック共重合体
FR2868784B1 (fr) * 2004-04-09 2006-05-26 Oreal Copolymere sequence, composition le comprenant et procede de traitement cosmetique
US7632905B2 (en) 2004-04-09 2009-12-15 L'oreal S.A. Block copolymer, composition comprising it and cosmetic treatment process
US20080274454A1 (en) 2004-04-07 2008-11-06 Mirkin Chad A Reversible and Chemically Programmable Micelle Assembly With Dna Block-Copolymer Amphiphiles
US8821859B2 (en) 2004-05-19 2014-09-02 Agency For Science, Technology And Research Methods and articles for the delivery of therapeutic agents
WO2006060723A2 (en) 2004-12-03 2006-06-08 Vical Incorporated Methods for producing block copolymer/amphiphilic particles
WO2006071769A1 (en) 2004-12-28 2006-07-06 The Trustees Of The University Of Pennsylvania Controlled release from block co-polymer worm micelles
US20060171980A1 (en) 2005-02-01 2006-08-03 Helmus Michael N Implantable or insertable medical devices having optimal surface energy
JP2008534747A (ja) 2005-03-31 2008-08-28 エーピー ファーマ， インコーポレイテッド Ｐｅｇ−ポリアセタールグラフトコポリマーおよびｐｅｇ−ポリアセタール−ｐｏｅグラフトコポリマーならびに医薬組成物
US8574604B2 (en) 2005-04-15 2013-11-05 Interface Biologics, Inc. Methods and compositions for the delivery of biologically active agents
US9139850B2 (en) 2005-05-19 2015-09-22 L'oreal Vectorization of dsRNA by cationic particles and topical use
JP5329949B2 (ja) 2005-05-31 2013-10-30 エコーレ ポリテクニーク フェデラーレ デ ローザンヌ 遺伝子に基づいた薬物の細胞質送達のためのトリブロックコポリマー
FR2890859B1 (fr) 2005-09-21 2012-12-21 Oreal Oligonucleotide d'arn double brin inhibant l'expression de la tyrosinase
EP2019691B1 (en) 2006-05-15 2020-08-12 Massachusetts Institute of Technology Polymers for functional particles
WO2008004978A1 (en) 2006-07-05 2008-01-10 Agency For Science, Technology And Research Micelles for drug delivery
WO2008022309A2 (en) 2006-08-18 2008-02-21 F. Hoffmann-La Roche Ag Polyconjugates for in vivo delivery of polynucleotides
US8414926B1 (en) 2006-09-12 2013-04-09 University Of South Florida Nanoparticles with covalently bound surfactant for drug delivery
US20080081075A1 (en) 2006-10-02 2008-04-03 National Tsing Hua University Multifunctional mixed micelle of graft and block copolymers and preparation thereof
US20100137206A1 (en) 2006-12-15 2010-06-03 The Governors Of The University Of Alberta Novel ligand guided block copolymers for targeted drug delivery
WO2008088658A2 (en) 2007-01-17 2008-07-24 Immunomedics, Inc. Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
US20080299177A1 (en) 2007-06-06 2008-12-04 Biovaluation & Analysis, Inc. Supramolecular Complexes for Use in Acoustically Mediated Intracellular Drug Delivery in vivo
JP2010529047A (ja) 2007-06-08 2010-08-26 クィーンズランド ユニバーシティ オブ テクノロジー 創傷修復組成物および方法
EP2173168A1 (en) 2007-06-11 2010-04-14 BioCure, Inc. Vesicles for active macromolecule delivery
KR20100037120A (ko) 2007-07-06 2010-04-08 노스이스턴 유니버시티 Ｒｎａ 작용제의 양쪽성 컨주게이트를 포함하는 혼합 미쎌, 및 이의 용도
US20090036625A1 (en) 2007-08-01 2009-02-05 Chung Yuan Christian University Amphiphilic Polymer, Method for Forming the Same and Application thereof
EP2025348A1 (en) 2007-08-13 2009-02-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Targeted block copolymer micelles
JP5755563B2 (ja) 2008-05-13 2015-07-29 ユニヴァーシティ オブ ワシントン ミセル集合体
AU2009246327B8 (en) * 2008-05-13 2013-10-03 Phaserx, Inc. Diblock copolymers and polynucleotide complexes thereof for delivery into cells
JP2011520901A (ja) 2008-05-13 2011-07-21 ユニヴァーシティ オブ ワシントン 治療剤の細胞内送達のためのミセル
EP2296708A4 (en) 2008-05-13 2011-10-26 Univ Washington POLYMER CARRIER
WO2009140423A2 (en) 2008-05-13 2009-11-19 University Of Washington Targeted polymer bioconjugates
US9211250B2 (en) 2008-08-22 2015-12-15 University Of Washington Heterogeneous polymeric micelles for intracellular delivery
EP2180004B1 (en) 2008-10-22 2011-05-18 Clariant Finance (BVI) Limited Olefinically unsaturated phosphonate compounds, polymers made therefrom and their use
AU2009313358B2 (en) 2008-11-06 2013-06-06 Phaserx, Inc. Multiblock copolymers
CA2742955A1 (en) * 2008-11-06 2010-05-14 University Of Washington Bispecific intracellular delivery vehicles
WO2010053597A2 (en) 2008-11-06 2010-05-14 University Of Washington/////////////////////-+ Micelles of hydrophilically shielded membrane-destabilizing copolymers
US20100150952A1 (en) 2008-11-07 2010-06-17 University Of Washington pH-RESPONSIVE POLYMER CARRIER COMPOSITIONS FOR CYTOSOLIC PROTEIN DELIVERY
EP2373715A4 (en) 2008-12-08 2014-12-03 Univ Washington OMEGA FUNCTIONALIZED POLYMERS, TRANSITIONALIZED BLOCK COPOLYMERS, POLYMER BIOKON JUGATES, AND RADICAL CHAIN EXTENSION POLICY RESPONSE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006016166A1 (en) * 2004-08-13 2006-02-16 Asahi Kasei Kabushiki Kaisha Polymers useful as medical materials
US20070224241A1 (en) * 2006-03-16 2007-09-27 Washington, University Of TEMPERATURE- AND pH-RESPONSIVE POLYMER COMPOSITIONS

Also Published As

Publication number Publication date
IL209238A (en) 2014-03-31
IL209238A0 (en) 2011-01-31
JP2016053169A (ja) 2016-04-14
EP2620161A1 (en) 2013-07-31
WO2009140427A3 (en) 2010-03-04
BRPI0912159B8 (pt) 2021-05-25
ES2404131T3 (es) 2013-05-24
US9862792B2 (en) 2018-01-09
AU2009246327A1 (en) 2009-11-19
CA2972694A1 (en) 2009-11-19
AU2009246327B8 (en) 2013-10-03
KR101661636B1 (ko) 2016-09-30
ZA201008729B (en) 2014-05-28
BRPI0912159A2 (pt) 2015-10-13
CA3065577A1 (en) 2009-11-19
CA2724105A1 (en) 2009-11-19
US9476063B2 (en) 2016-10-25
EP2281011A4 (en) 2011-10-26
MX2010012238A (es) 2011-04-11
AU2009246327A8 (en) 2011-01-13
US20110143434A1 (en) 2011-06-16
WO2009140427A2 (en) 2009-11-19
KR20110033124A (ko) 2011-03-30
JP6239565B2 (ja) 2017-11-29
US20180171056A1 (en) 2018-06-21
BRPI0912159B1 (pt) 2019-11-05
US20170096517A1 (en) 2017-04-06
AU2009246327B2 (en) 2013-09-12
EP2281011A2 (en) 2011-02-09
JP2011521054A (ja) 2011-07-21
CN102083878B (zh) 2013-07-10
CA2724105C (en) 2017-09-05
CN102083878A (zh) 2011-06-01
CN103342789A (zh) 2013-10-09
CA2972694C (en) 2020-02-11
EP2281011B1 (en) 2013-02-27
JP5911723B2 (ja) 2016-04-27
CA3065577C (en) 2022-05-31

Similar Documents

Publication Publication Date Title
CN103342789B (zh) 用于向细胞内递送的二嵌段共聚物和其多核苷酸复合物
Kim et al. Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid
CN102066444A (zh) 胶束装配体
CN108064156B (zh) 抑制Hif2α基因表达的组合物及方法
CN102076328A (zh) 用于胞内递送治疗剂的胶束
US7718432B2 (en) Non-immunogenic, hydrophilic/cationic block copolymers and uses thereof
Holley et al. Block ionomer complexes consisting of siRNA and aRAFT-synthesized hydrophilic-block-cationic copolymers: the influence of cationic block length on gene suppression
AU2013204733C1 (en) Diblock copolymers and polynucleotide complexes thereof for delivery into cells
Averick et al. Auto-transfecting siRNA through Facile Covalent Polymer Escorts
Holley Utilization of Aqueous RAFT Prepared Copolymers to Improve Anticancer Drug Efficacy
Zhou Design of polymer motifs for nucleic acid recognition and assembly stabilization
Jia Improving the biopharmaceutical properties of oligonucleotides and oligopeptides through polymer conjugation and architecture design
Holley Utilization of aqueous raft synthesized copolymers to improve anticancer drug efficacy
Hoffman Nanoscale Radiation Engineering of Advanced Materials for Potential Biomedical Applications
York Synthesis of functional copolymers via aqueous RAFT polymerization for bioconjugation and targeted delivery of small interfering RNA

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20161123

Termination date: 20200513

CF01 Termination of patent right due to non-payment of annual fee